1. In vivo effect of KIN-193 on PTEN-deficient tumors.
In vivo effect of KIN-193 on PTEN-deficient tumors. A–C, xenograft tumor growth curves of HCC70, PC3, and HCC1954 treated with vehicle or KIN-193 (i.p., 20 mg/kg, twice a day) or GDC-0941 [orally, 150 mg/kg, per day (HCC1954 tumors)] as indicated. The data are represented as mean ± SEM (n = 10). *P < 0.05, **P < 0.01 (Student t test). D–F, immunohistochemistry analyses of pAKTS473 and Ki67 on xenograft tumor samples of HCC70, PC3, and HCC1954 treated with vehicle, KIN-193 (i.p., 20 mg/kg, twice a day), or GDC-0941 (orally, 150 mg/kg, per day) for 4 days. Tumors were collected 1 hour after the last dosing, fixed, and subjected to immunohistochemistry analysis. Scale bar, 10 μm.
Jing Ni et al. Cancer Discovery 2012;2:
©2012 by American Association for Cancer Research